Burke William Patrick 4

4 · NovoCure Ltd · Filed Mar 7, 2022

Form 4

Period: 2022-03-03

Chief Human Resources Officer

Transactions

Award
Ordinary Shares
2022-03-03+7,445→ 58,395 total
Sale
Ordinary Shares
2022-03-03$74.50/sh−341$25,404→ 58,054 total
Sale
Ordinary Shares
2022-03-04$70.41/sh−1,026$72,238→ 57,028 total
Award
Options to Buy Ordinary Shares
2022-03-03$80.59/sh+13,038$1,050,732→ 13,038 total
Exercise: $80.59From: 2023-03-01Exp: 2032-02-29→ Ordinary Shares (13,038 underlying)
Award
Options to Buy Ordinary Shares
2022-03-03$80.59/sh+4,361$351,453→ 4,361 total
Exercise: $80.59From: 2023-03-01Exp: 2032-02-29→ Ordinary Shares (4,361 underlying)

Footnotes (4)

[F1]Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
[F2]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
[F3]Options to buy 13,038 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
[F4]Options to buy 4,361 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.

Documents

2 files